Day three of ASCO 2019 saw a showdown between two anti-CD38 compounds in multiple myeloma, Janssen's Darzalex and Sanofi's isatuximab. Darzalex showed more positive data in newly-d
Exclusive live coverage from day one of the American Society of Clinical Oncology's annual meeting in Chicago. • To view all of our coverage from the preeminent cancer event, produ
Exclusive live coverage from day two of the American Society of Clinical Oncology's annual meeting in Chicago. • To view all of our coverage from the preeminent cancer event, produ
Exclusive live coverage from day three of the American Society of Clinical Oncology's annual meeting in Chicago. • To view all of our coverage from the preeminent cancer event, pro
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
